Aurora Cannabis Denies AI-Generated $215M Acquisition, Partnership Reports

Aurora Cannabis has strongly denied two recent news reports claiming the company agreed to acquire New Zealand-based MedLeaf Therapeutics for $215 million and entered a strategic partnership with MediPharm GmbH to distribute medical cannabis in Europe. The company clarified that neither acquisition talks nor partnership discussions have taken place and emphasized these articles, published on Investing.com and generated with AI support, are entirely false. Aurora is investigating the origin of these misleading reports and has warned investors not to consider Investing.com a credible source for company information. Despite reporting strong quarterly results, Aurora's shares dropped over 20% following the misinformation. Analysts currently rate Aurora Cannabis as an 'Outperform' with mixed price target estimates indicating both downside and upside potential. The company reiterated that any material corporate transactions will be communicated directly to the market when appropriate.